Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Akeso Biomedical
Thumbnail
May 27, 2022

Asco 2022 – great expectations for Adicet, Arcellx and PMV

Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.

Thumbnail
May 03, 2022

China-backed US approvals continue to hang in the balance

Article image
Vantage logo
February 11, 2022

How China applicants could avoid the sintilimab scenario

A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.

Article image
Vantage logo
January 04, 2022

Days of reckoning for immune checkpoint blockers

Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.

Article image
Vantage logo
November 04, 2020

SITC 2020 – second chances for Merck & Co and Oncosec

Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.

Article image
Vantage logo
February 14, 2020

Astra turns to bispecifics to solve the treme problem

Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.

Article image
Vantage logo
October 09, 2019

SITC 2019 preview – Nextcure’s time to shine

The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.